Company intelligence / Profile preview

64x Bio

Brisbane, California, United States64xbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s VectorSelect™ platform is designed to dramatically improve the yield, quality, and scalability of viral vector production for gene therapy manufacturing. No direct clinical results are reported as the company provides enabling technologies rather than therapeutic products[6][1].

Therapeutic areas: Other
Modalities: Engineered mammalian cell lines for viral vector production (enabling gene and cell therapies)
Industry: Non-Drug Biotech

Partnerships

Partnerships with leading gene therapy companies and CDMOs are referenced but not specifically named[1][6].

Beyond the preview

Go deeper on 64x Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 64x Bio.

Explore the full profile